Vaxcell-Bio Therapeutics박셀바이오
323990 · KOSDAQ · ₩323990 · 박셀바이오
₩3,790▼ ₩165 (4.17%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 7.5% | 12.7% | 19.2% | 51.9% | — | — |
| Operating margin | −257.1% | −219.6% | −791.9% | −83,851.2% | — | — |
| Net margin | −229.1% | −189.1% | −559.4% | −74,865.8% | — | — |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −7.7% | +271.6% | +13,737.3% | — | — | — |
| Operating income growth | −8.0% | −3.1% | −30.7% | −40.1% | −39.1% | — |
| Net income growth | −11.8% | −25.6% | −3.4% | −50.5% | −43.3% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −26.1% | −20.0% | −13.7% | −19.2% | −25.6% | −15.8% |
| Return on assets | −23.8% | −18.5% | −13.1% | −18.8% | −24.6% | −15.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 10.1% | 9.4% | 6.9% | 1.8% | 3.6% | 4.0% |
| Net debt to equity | −24.6% | −34.4% | −47.6% | −59.2% | −0.9% | −7.1% |
| Current ratio | 556.4% | 852.9% | 1,386.6% | 5,543.2% | 6,806.4% | 7,187.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Vaxcell-Bio Therapeutics / 박셀바이오 / 323990 / KRX:323990
Source: KRX statistical information